Glucotrack's Implantable Glucose Monitor Shows Long-Term Accuracy in Ovine Study
Event summary
- Glucotrack published a peer-reviewed study in the Journal of Diabetes Research demonstrating its implantable continuous blood glucose monitor (CBGM) maintained accuracy over 240 days in an ovine model.
- The study showed a weighted average Mean Absolute Relative Difference (MARD) of 6.8% across 79 tests with no device-related adverse safety events observed.
- Glucotrack's CBGM system is designed for long-term use with a sensor longevity of 3 years and minimal calibration requirements.
- The company plans to submit an Investigational Device Exemption (IDE) application with the FDA, advancing its path toward clinical development and commercialization.
The big picture
Glucotrack's successful long-term accuracy study reinforces its position in the competitive diabetes management market, where continuous glucose monitoring is increasingly critical. The shift toward implantable devices with extended sensor life could disrupt traditional wearable solutions, provided regulatory and commercial hurdles are cleared.
What we're watching
- Regulatory Progress
- The pace at which Glucotrack advances its IDE submission and secures FDA approval will determine the timeline for clinical trials.
- Market Differentiation
- Whether Glucotrack's long-term accuracy and stability data can position it as a leader in the implantable glucose monitoring space.
- Commercial Viability
- How the company’s ability to scale manufacturing and distribution will impact its path to commercialization.
Our editorial coverage:
Related topics